¸¶¿ì½º ¸ðµ¨ ½ÃÀå : ¸ðµ¨ À¯Çüº°, ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Mice Model Market, By Model Type, By Service, By Technology, By Application, By End User, By Geography
»óǰÄÚµå : 1812411
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,376,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,919,000
PDF & Excel (Multi User License - Up to 7 Users) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ÃÖ´ë 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,171,000
PDF & Excel (Corporate User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº 2025³â¿¡´Â 18¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 36¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀ̸ç, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 9.9%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 18¾ï 6,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2020-2024³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR 9.90% 2032³â °¡Ä¡ ¿¹Ãø 36¾ï ´Þ·¯

¼¼°è ¸¶¿ì½º ¸ðµ¨ ½ÃÀåÀº ±¤¹üÀ§ÇÑ »ý¹° ÀÇÇÐ ¿¬±¸ »ýŰ迡¼­ Áß¿äÇÑ ºÎºÐÀ» Â÷ÁöÇϰí ÀÖÀ¸¸ç, °úÇÐÀû ¹ß°ß°ú ÀǾàǰ °³¹ß¿¡ ÇʼöÀûÀÎ µµ±¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÇÇè¿ë ¸¶¿ì½º, ƯÈ÷ À¯ÀüÀÚ º¯Çü °èÅëÀÇ ¸¶¿ì½º´Â Àΰ£°úÀÇ À¯ÀüÀû À¯»ç¼º, Àß Æ¯¼ºÈ­µÈ »ý¹°ÇÐÀû ½Ã½ºÅÛ, È®¸³µÈ ¿¬±¸ ÇÁ·ÎÅäÄÝ·Î ÀÎÇØ ÀüÀÓ»ó ¿¬±¸ÀÇ Ç¥ÁØÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ±ÙÄ£±³¹è ¸¶¿ì½º, ±ÙÄ£±³¹è ¸¶¿ì½º, À¯ÀüÀÚ º¯Çü ¸ðµ¨ ¸¶¿ì½º(GEM), ¸é¿ª°áÇÌ ¸¶¿ì½º µî ´Ù¾çÇÑ ¸¶¿ì½º ¸ðµ¨ÀÌ ÀÖÀ¸¸ç, °¢°¢ ƯÁ¤ Àΰ£ÀÇ Áúº´À̳ª »óŸ¦ ÀçÇöÇϵµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ, ¾Ï, ½Å°æÁúȯ, ´ë»ç¼º ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ Àΰ£ÀÇ º´Å»ý¸®¸¦ Á¤È®ÇÏ°Ô ¸ð¹æÇÒ ¼ö Àִ ÷´Ü µ¿¹° ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Çмú±â°ü, Á¦¾àȸ»ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, À§Å¹¿¬±¸±â°üÀº ½Å¾à°³¹ß, µ¶¼ºÇÐ ¿¬±¸, À¯È¿¼º ½ÃÇè, ¸ÂÃãÇü ÀǷῬ±¸¸¦ À§ÇØ ÀÌ ¸ðµ¨¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¼ºÀåÀº CRISPR-Cas9¿Í °°Àº À¯Àü°øÇÐ ±â¼úÀÇ ±â¼úÀû Áøº¸¿¡ ÀÇÇØ ´õ¿í ÃËÁøµÉ °ÍÀÔ´Ï´Ù. CRISPR-Cas9Àº º¸´Ù Á¤¹ÐÇϰí Áúº´¿¡ ƯȭµÈ ¸¶¿ì½º ¸ðµ¨ °³¹ßÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ¿¬±¸ ¼º°ú¸¦ Çâ»ó½Ã۰í, ¿¬±¸½Ç¿¡¼­ÀÇ ¹ß°ßÀ» ÀÓ»ó Àû¿ëÀ¸·Î ÀüȯÇÏ´Â °ÍÀ» °¡¼ÓÈ­ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ¸¶¿ì½º ¸ðµ¨ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ßÀÇ °ßÁ¶ÇÑ È®ÀåÀ» ÃËÁøÇÏ´Â ¸î °¡Áö ¸Å·ÂÀûÀÎ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ±× ù ¹øÂ° ¿äÀÎÀº ½Å¾à °³¹ß Ȱµ¿ÀÇ ±Þ°ÝÇÑ ¼ºÀåÀ¸·Î, Á¦¾à»çµéÀº Àΰ£ ´ë»ó ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϱâ Àü¿¡ Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» Æò°¡Çϱâ À§ÇØ Á¤±³ÇÑ ¸¶¿ì½º ¸ðµ¨¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¾Ï, ´ç´¢, ½ÉÇ÷°üÁúȯ, ½Å°æÁúȯ µî ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇØ Àΰ£ÀÇ º´Å»ý¸®¸¦ Á¤È®ÇÏ°Ô ÀçÇöÇÒ ¼ö ÀÖ´Â Áúȯ ƯÀÌÀû ¸¶¿ì½º ¸ðµ¨ °³¹ßÀÌ ÇÊ¿äÇØÁö¸é¼­ ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, À¯Àü°øÇÐ, ƯÈ÷ CRISPR-Cas9 ¹× ±âŸ À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀüÀº À¯ÀüÀÚ º¯Çü ¸¶¿ì½º ¸ðµ¨ Á¦ÀÛ¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ¿¬±¸ÀÚµéÀÌ º¸´Ù Á¤¹ÐÇϰí Ç¥ÀûÈ­µÈ ½ÇÇè ½Ã½ºÅÛÀ» °³¹ßÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ¼ºÀå ±Ëµµ¸¦ Èçµé ¼ö ÀÖ´Â Å« ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. À±¸®ÀûÀÎ °í·Á»çÇ×°ú ÄÄÇöóÀ̾𽺠¿ä°Ç µî µ¿¹°½ÇÇèÀ» °ü¸®ÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå È®´ëÀÇ À庮ÀÌ µÇ°í, ¿¬±¸±â°üÀÇ ¿î¿µºñ¿ëÀ» Áõ°¡½ÃŰ´Â ¿äÀÎÀÌ µË´Ï´Ù. in-vitro ¸ðµ¨, Àå±â ¿ÂĨ ±â¼ú, °è»ê ¸ðµ¨¸µ°ú °°Àº ´ëü ½ÃÇè¹ýÀÌ °­Á¶µÇ¸é¼­ ÀüÅëÀûÀÎ µ¿¹° ±â¹Ý ¿¬±¸ ÆÐ·¯´ÙÀÓ¿¡ ´ëÇÑ ÀáÀçÀû À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ư¼ö ¸¶¿ì½º °èÅëÀÇ ¹ø½Ä, À¯Áö, »çÀ°°ú °ü·ÃµÈ ³ôÀº ºñ¿ë°ú Ư¼öÇÑ ½Ã¼³ ¹× ÈÆ·ÃµÈ ÀηÂÀÇ Çʿ伺ÀÌ °áÇÕµÇ¾î ¼Ò±Ô¸ð ¿¬±¸ Á¶Á÷ÀÌ ½±°Ô ÀÌ¿ëÇÒ ¼ö Àִ ȯ°æÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí, ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÂÃãÇü Ä¡·á¹ý °³¹ßÀ» À§Çؼ­´Â ȯÀÚº° ¸¶¿ì½º ¸ðµ¨ÀÌ ÇÊ¿äÇϸç, ÀÌ´Â Å« ºñÁî´Ï½º ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Àü¹® ¸¶¿ì½º ¸ðµ¨ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ¼öŹ ¿¬±¸±â°üÀÇ È®´ë´Â ƯÈ÷ ¿¬±¸ ÀÎÇÁ¶ó°¡ ºü¸£°Ô ¹ßÀüÇϰí ÀÖ´Â ½ÅÈï±¹ ½ÃÀå¿¡¼­ ½ÃÀå ¼ºÀåÀÇ ±âȸ·Î ÀÛ¿ëÇÒ °ÍÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå, ¸ðµ¨ À¯Çüº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå, ¼­ºñ½ºº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå, ±â¼úº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå, ¿ëµµº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ ¸¶¿ì½º ¸ðµ¨ ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

Á¦12Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Mice Model Market is estimated to be valued at USD 1.86 Bn in 2025 and is expected to reach USD 3.60 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.86 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 9.90% 2032 Value Projection: USD 3.60 Bn

The global mice model market represents a critical segment within the broader biomedical research ecosystem, serving as an indispensable tool for scientific discovery and pharmaceutical development. Laboratory mice, particularly genetically modified strains, have become the gold standard for preclinical research due to their genetic similarity to humans, well-characterized biological systems, and established research protocols. This market encompasses various mouse models including inbred strains, outbred stocks, Genetically Engineered Models (GEMs), and immunodeficient mice, each designed to replicate specific human diseases and conditions.

The increasing prevalence of chronic diseases, cancer, neurological disorders, and metabolic conditions has intensified the demand for sophisticated animal models that can accurately mimic human pathophysiology. Academic institutions, pharmaceutical companies, biotechnology firms, and contract research organizations heavily rely on these models for drug discovery, toxicology studies, efficacy testing, and personalized medicine research. The market's growth is further propelled by technological advancements in genetic engineering techniques such as CRISPR-Cas9, which enable the development of more precise and disease-specific mouse models, thereby enhancing research outcomes and accelerating the translation of laboratory findings into clinical applications.

Market Dynamics

The global mice model market growth is driven by several compelling factors that collectively fuel its robust expansion across the pharmaceutical and biotechnology sectors. The primary driver stems from the exponential growth in drug discovery and development activities, where pharmaceutical companies increasingly rely on sophisticated mouse models to evaluate therapeutic efficacy and safety profiles before advancing to human trials. The rising prevalence of chronic diseases, including cancer, diabetes, cardiovascular disorders, and neurological conditions, necessitates the development of disease-specific mouse models that can accurately replicate human pathophysiology, thereby driving market demand.

Additionally, technological advancements in genetic engineering, particularly CRISPR-Cas9 and other gene-editing technologies, have revolutionized the creation of genetically modified mouse models, enabling researchers to develop more precise and targeted experimental systems. However, the market faces significant restraints that challenge its growth trajectory. Stringent regulatory frameworks governing animal research, including ethical considerations and compliance requirements, create barriers for market expansion and increase operational costs for research institutions. The growing emphasis on alternative testing methods, such as in-vitro models, organ-on-chip technologies, and computational modeling, poses a potential threat to traditional animal-based research paradigms. Furthermore, the high costs associated with breeding, maintaining, and housing specialized mouse strains, coupled with the need for specialized facilities and trained personnel, limit accessibility for smaller research organizations.

Despite these challenges, substantial opportunities emerge from the increasing adoption of personalized medicine approaches, which require patient-specific mouse models for tailored therapeutic development. The expansion of contract research organizations offering specialized mouse model services presents lucrative opportunities for market growth, particularly in emerging markets where research infrastructure is rapidly developing.

Key Features of the Study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Mice Model Market, By Model Type, 2020-2032, (USD Bn)

5. Global Mice Model Market, By Service, 2020-2032, (USD Bn)

6. Global Mice Model Market, By Technology, 2020-2032, (USD Bn)

7. Global Mice Model Market, By Application, 2020-2032, (USD Bn)

8. Global Mice Model Market, By End User, 2020-2032, (USD Bn)

9. Global Mice Model Market, By Region, 2020 - 2032, Value (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â